Low – not high – levels of testosterone may be new culprit in prostate cancer
September 6, 2009 by Jim Tucker
URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>
Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.
Like this:
Like Loading...
Posted in Diagnosis, Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Testosterone treatment, Treatment debate | Tagged advanced stage of presentation, androgen-deprivation therapy, cancer research, high Gleason score, high serum testosterone, Hormone therapy, increased risk of biochemical recurrence after surgery, low serum testosterone, new testosterone evidence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, testosterone, testosterone levels, URO TODAY, worrisome cancer features | Leave a Comment
Leave a Reply
